|
|
.
CodeMap® Compliance Briefing: October 31, 2019
Editor's Welcome: The following CodeMap® Compliance Briefing will discuss several recent developments that should be of concern to clinical laboratories that specialize in drug testing or toxicology. Although most providers of drug testing try to maintain a culture of compliance and ethics, some unscrupulous players continue to commit fraudulent billing practices and provide illegal kickbacks to referral sources. As a result, the OIG and DOJ continue to target these laboratories. In addition to discussing recent enforcement actions concerning drug testing laboratories, this CodeMap® Briefing will also explore the OIG's latest intentions to examine on a global basis Medicare claims and payments for Part B urine drug testing. As always, please forward any comments, ....
Sorry, the full document you are trying to access requires an active subscription.
Please login to the left.
|
